Cargando…
Clinical implication of ZEB-1 and E-cadherin expression in hepatocellular carcinoma (HCC)
BACKGROUND: While recent research has shown that expression of ZEB-1 in a variety of tumors has a crucial impact on patient survival, there is little information regarding ZEB-1 expression in hepatocellular carcinoma (HCC). This study investigated the co-expression of ZEB-1 and E-cadherin in HCC by...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4235016/ https://www.ncbi.nlm.nih.gov/pubmed/24304617 http://dx.doi.org/10.1186/1471-2407-13-572 |
_version_ | 1782344950844751872 |
---|---|
author | Hashiguchi, Motoyuki Ueno, Shinichi Sakoda, Masahiko Iino, Satoshi Hiwatashi, Kiyokazu Minami, Koji Ando, Kei Mataki, Yuko Maemura, Kosei Shinchi, Hiroyuki Ishigami, Sumiya Natsugoe, Shoji |
author_facet | Hashiguchi, Motoyuki Ueno, Shinichi Sakoda, Masahiko Iino, Satoshi Hiwatashi, Kiyokazu Minami, Koji Ando, Kei Mataki, Yuko Maemura, Kosei Shinchi, Hiroyuki Ishigami, Sumiya Natsugoe, Shoji |
author_sort | Hashiguchi, Motoyuki |
collection | PubMed |
description | BACKGROUND: While recent research has shown that expression of ZEB-1 in a variety of tumors has a crucial impact on patient survival, there is little information regarding ZEB-1 expression in hepatocellular carcinoma (HCC). This study investigated the co-expression of ZEB-1 and E-cadherin in HCC by immunohistochemistry and evaluated its association with clinical factors, including patient prognosis. METHODS: A total of 108 patients with primary HCC treated by curative hepatectomy were enrolled. ZEB-1 expression was immunohistochemically categorized as positive if at least 1% cancer cells exhibited nuclear staining. E-cadherin expression was divided into preserved and reduced expression groups and correlations between ZEB-1 and E-cadherin expression and clinical factors were then evaluated. RESULTS: With respect to ZEB-1 expression, 23 patients were classified into the positive group and 85 into the negative group. Reduced E-cadherin expression was seen in 44 patients and preserved expression in the remaining 64 patients. ZEB-1 positivity was significantly associated with reduced expression of E-cadherin (p = 0.027). Moreover, significant associations were found between ZEB-1 expression and venous invasion and TNM stage. ZEB-1 positivity was associated with poorer prognosis (p = 0.025). Reduced E-cadherin expression was significantly associated with intrahepatic metastasis and poorer prognosis (p = 0.047). In particular, patients with both ZEB-1 positivity and reduced E-cadherin expression had a poorer prognosis (p = 0.005). Regardless of E-cadherin status, ZEB-1 was not a significant prognostic factor by multivariate analysis. There was no statistical difference in overall survival when E-cadherin expression was reduced in the ZEB-1 positive group (p = 0.24). CONCLUSIONS: Positive ZEB-1 expression and loss of E-cadherin expression are correlated with poor prognosis in HCC patients and malignancy of ZEB-1 positive tumors involves EMT. |
format | Online Article Text |
id | pubmed-4235016 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-42350162014-11-19 Clinical implication of ZEB-1 and E-cadherin expression in hepatocellular carcinoma (HCC) Hashiguchi, Motoyuki Ueno, Shinichi Sakoda, Masahiko Iino, Satoshi Hiwatashi, Kiyokazu Minami, Koji Ando, Kei Mataki, Yuko Maemura, Kosei Shinchi, Hiroyuki Ishigami, Sumiya Natsugoe, Shoji BMC Cancer Research Article BACKGROUND: While recent research has shown that expression of ZEB-1 in a variety of tumors has a crucial impact on patient survival, there is little information regarding ZEB-1 expression in hepatocellular carcinoma (HCC). This study investigated the co-expression of ZEB-1 and E-cadherin in HCC by immunohistochemistry and evaluated its association with clinical factors, including patient prognosis. METHODS: A total of 108 patients with primary HCC treated by curative hepatectomy were enrolled. ZEB-1 expression was immunohistochemically categorized as positive if at least 1% cancer cells exhibited nuclear staining. E-cadherin expression was divided into preserved and reduced expression groups and correlations between ZEB-1 and E-cadherin expression and clinical factors were then evaluated. RESULTS: With respect to ZEB-1 expression, 23 patients were classified into the positive group and 85 into the negative group. Reduced E-cadherin expression was seen in 44 patients and preserved expression in the remaining 64 patients. ZEB-1 positivity was significantly associated with reduced expression of E-cadherin (p = 0.027). Moreover, significant associations were found between ZEB-1 expression and venous invasion and TNM stage. ZEB-1 positivity was associated with poorer prognosis (p = 0.025). Reduced E-cadherin expression was significantly associated with intrahepatic metastasis and poorer prognosis (p = 0.047). In particular, patients with both ZEB-1 positivity and reduced E-cadherin expression had a poorer prognosis (p = 0.005). Regardless of E-cadherin status, ZEB-1 was not a significant prognostic factor by multivariate analysis. There was no statistical difference in overall survival when E-cadherin expression was reduced in the ZEB-1 positive group (p = 0.24). CONCLUSIONS: Positive ZEB-1 expression and loss of E-cadherin expression are correlated with poor prognosis in HCC patients and malignancy of ZEB-1 positive tumors involves EMT. BioMed Central 2013-12-05 /pmc/articles/PMC4235016/ /pubmed/24304617 http://dx.doi.org/10.1186/1471-2407-13-572 Text en Copyright © 2013 Hashiguchi et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Hashiguchi, Motoyuki Ueno, Shinichi Sakoda, Masahiko Iino, Satoshi Hiwatashi, Kiyokazu Minami, Koji Ando, Kei Mataki, Yuko Maemura, Kosei Shinchi, Hiroyuki Ishigami, Sumiya Natsugoe, Shoji Clinical implication of ZEB-1 and E-cadherin expression in hepatocellular carcinoma (HCC) |
title | Clinical implication of ZEB-1 and E-cadherin expression in hepatocellular carcinoma (HCC) |
title_full | Clinical implication of ZEB-1 and E-cadherin expression in hepatocellular carcinoma (HCC) |
title_fullStr | Clinical implication of ZEB-1 and E-cadherin expression in hepatocellular carcinoma (HCC) |
title_full_unstemmed | Clinical implication of ZEB-1 and E-cadherin expression in hepatocellular carcinoma (HCC) |
title_short | Clinical implication of ZEB-1 and E-cadherin expression in hepatocellular carcinoma (HCC) |
title_sort | clinical implication of zeb-1 and e-cadherin expression in hepatocellular carcinoma (hcc) |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4235016/ https://www.ncbi.nlm.nih.gov/pubmed/24304617 http://dx.doi.org/10.1186/1471-2407-13-572 |
work_keys_str_mv | AT hashiguchimotoyuki clinicalimplicationofzeb1andecadherinexpressioninhepatocellularcarcinomahcc AT uenoshinichi clinicalimplicationofzeb1andecadherinexpressioninhepatocellularcarcinomahcc AT sakodamasahiko clinicalimplicationofzeb1andecadherinexpressioninhepatocellularcarcinomahcc AT iinosatoshi clinicalimplicationofzeb1andecadherinexpressioninhepatocellularcarcinomahcc AT hiwatashikiyokazu clinicalimplicationofzeb1andecadherinexpressioninhepatocellularcarcinomahcc AT minamikoji clinicalimplicationofzeb1andecadherinexpressioninhepatocellularcarcinomahcc AT andokei clinicalimplicationofzeb1andecadherinexpressioninhepatocellularcarcinomahcc AT matakiyuko clinicalimplicationofzeb1andecadherinexpressioninhepatocellularcarcinomahcc AT maemurakosei clinicalimplicationofzeb1andecadherinexpressioninhepatocellularcarcinomahcc AT shinchihiroyuki clinicalimplicationofzeb1andecadherinexpressioninhepatocellularcarcinomahcc AT ishigamisumiya clinicalimplicationofzeb1andecadherinexpressioninhepatocellularcarcinomahcc AT natsugoeshoji clinicalimplicationofzeb1andecadherinexpressioninhepatocellularcarcinomahcc |